XBIOWXenetic Biosciences, Inc.
Data unavailable—Mkt Cap: —P/E: —805d ago
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing tr…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)2.44M $
Gross Profit2.44M $
Net Income (TTM)-2.68M $
Revenue/Share1.594 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.11
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-248.31%
EBITDA Margin0.00%
Profit Margin-90.07%
ROE-36.25%
ROA-32.05%
Growth
Revenue Growth-15.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.29M $
CapEx (TTM)—
FCF Margin-105.00%
FCF Yield—
Net Debt-7.82M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio11.69
Quick Ratio10.92
Book Value/Sh5.631 USD
Cash/Share5.078 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float1.18M
Insiders—
Institutions—
Technical
SMA 5012.44 USD
SMA 2009.052 USD
Beta2.30
S&P 52W Chg14.29%
Avg Vol (30d)—
Avg Vol (10d)1.02K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—